Equities research analysts expect Nektar Therapeutics (NASDAQ:NKTR) to post sales of $25.45 million for the current fiscal quarter, according to Zacks. Six analysts have made estimates for Nektar Therapeutics’ earnings, with the lowest sales estimate coming in at $24.10 million and the highest estimate coming in at $27.64 million. Nektar Therapeutics posted sales of $38.02 million during the same quarter last year, which would indicate a negative year-over-year growth rate of 33.1%. The business is expected to report its next quarterly earnings report on Thursday, May 9th.
According to Zacks, analysts expect that Nektar Therapeutics will report full year sales of $109.43 million for the current year, with estimates ranging from $101.19 million to $127.00 million. For the next fiscal year, analysts expect that the company will report sales of $221.92 million, with estimates ranging from $117.62 million to $423.92 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research analysts that that provide coverage for Nektar Therapeutics.
Nektar Therapeutics (NASDAQ:NKTR) last issued its quarterly earnings data on Thursday, February 28th. The biopharmaceutical company reported ($0.57) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.70) by $0.13. Nektar Therapeutics had a return on equity of 50.22% and a net margin of 57.09%. The company had revenue of $39.83 million for the quarter, compared to the consensus estimate of $25.97 million. During the same quarter last year, the company earned ($0.21) earnings per share.
In other Nektar Therapeutics news, COO John Nicholson sold 63,000 shares of the stock in a transaction dated Monday, January 28th. The stock was sold at an average price of $42.82, for a total value of $2,697,660.00. Following the completion of the sale, the chief operating officer now directly owns 237,477 shares in the company, valued at $10,168,765.14. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, SVP Maninder Hora sold 2,386 shares of the stock in a transaction dated Tuesday, February 19th. The shares were sold at an average price of $42.39, for a total value of $101,142.54. Following the completion of the sale, the senior vice president now owns 99,374 shares of the company’s stock, valued at $4,212,463.86. The disclosure for this sale can be found here. Over the last quarter, insiders sold 241,824 shares of company stock valued at $10,249,993. 4.31% of the stock is currently owned by company insiders.
A number of institutional investors have recently added to or reduced their stakes in NKTR. FMR LLC raised its stake in Nektar Therapeutics by 8.5% in the fourth quarter. FMR LLC now owns 25,961,520 shares of the biopharmaceutical company’s stock valued at $853,355,000 after buying an additional 2,041,954 shares during the last quarter. Norges Bank purchased a new stake in Nektar Therapeutics in the fourth quarter valued at about $63,723,000. Vanguard Group Inc raised its stake in Nektar Therapeutics by 3.6% in the third quarter. Vanguard Group Inc now owns 18,922,650 shares of the biopharmaceutical company’s stock valued at $1,153,525,000 after buying an additional 660,907 shares during the last quarter. Deutsche Bank AG raised its stake in Nektar Therapeutics by 131.6% in the fourth quarter. Deutsche Bank AG now owns 947,004 shares of the biopharmaceutical company’s stock valued at $31,125,000 after buying an additional 538,170 shares during the last quarter. Finally, BB Biotech AG raised its stake in Nektar Therapeutics by 63.4% in the fourth quarter. BB Biotech AG now owns 1,380,975 shares of the biopharmaceutical company’s stock valued at $45,393,000 after buying an additional 535,975 shares during the last quarter. Institutional investors own 94.62% of the company’s stock.
Shares of NKTR stock opened at $35.15 on Friday. Nektar Therapeutics has a 1-year low of $29.22 and a 1-year high of $104.88. The stock has a market cap of $6.22 billion, a P/E ratio of 9.30 and a beta of 3.05. The company has a debt-to-equity ratio of 0.14, a quick ratio of 17.39 and a current ratio of 17.53.
Nektar Therapeutics Company Profile
Nektar Therapeutics, a biopharmaceutical company, develops drug candidates for cancer, auto-immune disease, and chronic pain in the United States. The company develops NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; and NKTR-214, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in Phase I to treat immuno-oncology.
See Also: What is a Reverse Stock Split?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.